ACRS
Aclaris Therapeutics Stock Analysis
AI Rating
- Quality1/10
- Growth↑ 6/10
- Value↓ 0/10
ACRS Growth
- Revenue Y/Y↓ -53.12%
- EPS Y/Y↑ 64.78%
- FCF Y/Y↓ -323.51%
ACRS Profitability
- Gross margin ↓ 9.70%
- EPS margin↓ -832.60%
- ROIC 5Y↓ -67.93%
ACRS Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 0.0
- Interest coverage↓ NA
Aclaris Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.